New hope for Hard-to-Treat myeloma: drug cocktail trial launches

NCT ID NCT04126200

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a targeted drug called belantamab mafodotin, alone or with other cancer medicines, in people with multiple myeloma that has returned or stopped responding to prior treatments. About 208 adults will take part to see if these combinations are safe and effective. The goal is to find better ways to control this blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Belantamab mafodotin (an antibody-drug conjugate) combined with other anti-cancer drugs
What this could lead to: If successful, this could offer new combination treatment options for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Combination therapies also carry higher risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Atlanta, Georgia, 30322, United States
GSK Investigational Site

Indianapolis, Indiana, 46202, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Grand Rapids, Michigan, 49546, United States
GSK Investigational Site

Madison, Wisconsin, 53792, United States
GSK Investigational Site

Porto Alegre, 90110-270, Brazil
GSK Investigational Site

Salvador, 41253-190, Brazil
GSK Investigational Site

São Paulo, 04537-080, Brazil
GSK Investigational Site

Vancouver, British Columbia, V5Z1M9, Canada
GSK Investigational Site

Halifax, Nova Scotia, B3H 1V7, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Lille, 59037, France
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Frankfurt, 60590, Germany
GSK Investigational Site

Hamburg, 20246, Germany
GSK Investigational Site

Kiel, 24105, Germany
GSK Investigational Site

Leipzig, 04103, Germany
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Mexico City, 01330, Mexico
GSK Investigational Site

Leeuwarden, 8934 AD, Netherlands
GSK Investigational Site

Utrecht, 3584 CX, Netherlands
GSK Investigational Site

Oslo, 0450, Norway
GSK Investigational Site

Gdansk, 80-214, Poland
GSK Investigational Site

Katowice, 40-519, Poland
GSK Investigational Site

Lodz, 93-513, Poland
GSK Investigational Site

Lublin, 20-081, Poland
GSK Investigational Site

Incheon, 21565, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 06351, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Badalona, 08916, Spain
GSK Investigational Site

Madrid, 28027, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

PamplonaNavarra, 31008, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Falun, SE-791 82, Sweden
GSK Investigational Site

Stockholm, SE-141 86, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.